(Q36689066)

15 August 2017

1 reference

title

The side effects of the prostaglandin analogues (English)

1 reference

15 August 2017

Gábor Holló

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Drug Safety

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

45-52

1 reference

A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Travoprost--a new prostaglandin analogue for the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Topical prostaglandin F(2alpha) analog induced poliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Latanoprost: experience of 2-year treatment in Scandinavia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Intraocular Pressure, Safety, and Quality of Life in Glaucoma Patients Switching to Latanoprost from Monotherapy Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A standardized approach for iris color determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Mechanism and clinical significance of prostaglandin-induced iris pigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Transcription of prostanoid receptor genes and cyclooxygenase enzyme genes in cultivated human iridial melanocytes from eyes of different colours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Increased periocular pigmentation with ocular hypotensive lipid use in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Bimatoprost-induced periocular skin hyperpigmentation: histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Cystoid macular edema in the era of ocular hypotensive lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Cystoid macular edema associated with ocular hypotensive lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Does timolol LA enhance the disrupting effect of travoprost on the blood-aqueous barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Medical therapy in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Management of glaucoma in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Vasoactive responses of U46619, PGF2alpha, latanoprost, and travoprost in isolated porcine ciliary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

An evaluation of the effect of unoprostone isopropyl 0.15% on ocular hemodynamics in normal-tension glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Deepening of lid sulcus from topical bimatoprost therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Iris cyst associated with topical administration of latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Iris cyst secondary to latanoprost mimicking iris melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

Abdominal cramp as an adverse effect of travoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.45

21 January 2018

Identifiers

DOI

10.1517/14740338.6.1.45

1 reference

15 August 2017

1 reference